349 related articles for article (PubMed ID: 26097049)
21. Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.
Minato A; Noguchi H; Tomisaki I; Fukuda A; Kubo T; Nakayama T; Fujimoto N
Cancer Control; 2018; 25(1):1073274818800269. PubMed ID: 30213195
[TBL] [Abstract][Full Text] [Related]
22. The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer.
Djaladat H; Bruins HM; Miranda G; Cai J; Skinner EC; Daneshmand S
BJU Int; 2014 Jun; 113(6):887-93. PubMed ID: 23906037
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
24. Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy.
Zareba P; Patterson L; Pandya R; Margel D; Hotte SJ; Mukherjee SD; Elavathil L; Daya D; Shayegan B; Pinthus JH
Urol Oncol; 2014 Oct; 32(7):975-80. PubMed ID: 25027682
[TBL] [Abstract][Full Text] [Related]
25. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
26. Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy.
Mitra AP; Alemozaffar M; Harris BN; Schuckman AK; Skinner EC; Daneshmand S
Urology; 2014 Dec; 84(6):1420-6. PubMed ID: 25306479
[TBL] [Abstract][Full Text] [Related]
27. Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens.
Cai T; Tiscione D; Verze P; Pomara G; Racioppi M; Nesi G; Barbareschi M; Brausi M; Gacci M; Luciani LG; Liguori G; Gontero P; Campodonico F; Simonato A; Boddi V; Di Stasi SM; Colombo R; Serretta V; Carmignani G; Malossini G; Altieri V; Carini M; Terrone C; Bassi P; Montorsi F; Ficarra V; Selli C; Mirone V; Bartoletti R
Urology; 2014 Nov; 84(5):1141-6. PubMed ID: 25239253
[TBL] [Abstract][Full Text] [Related]
28. Gender-specific outcomes of bladder cancer patients: a stage-specific analysis in a contemporary, homogenous radical cystectomy cohort.
Soave A; Dahlem R; Hansen J; Weisbach L; Minner S; Engel O; Kluth LA; Chun FK; Shariat SF; Fisch M; Rink M
Eur J Surg Oncol; 2015 Mar; 41(3):368-77. PubMed ID: 24674298
[TBL] [Abstract][Full Text] [Related]
29. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma.
Kim SP; Frank I; Cheville JC; Thompson RH; Weight CJ; Thapa P; Boorjian SA
J Urol; 2012 Aug; 188(2):405-9. PubMed ID: 22704101
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of perioperative lymphocyte-monocyte ratio in patients with bladder cancer undergoing radical cystectomy.
Yoshida T; Kinoshita H; Yoshida K; Mishima T; Yanishi M; Inui H; Komai Y; Sugi M; Inoue T; Murota T; Fukui K; Harada J; Kawa G; Matsuda T
Tumour Biol; 2016 Aug; 37(8):10067-74. PubMed ID: 26819209
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
Viers BR; Boorjian SA; Frank I; Tarrell RF; Thapa P; Karnes RJ; Thompson RH; Tollefson MK
Eur Urol; 2014 Dec; 66(6):1157-64. PubMed ID: 24630414
[TBL] [Abstract][Full Text] [Related]
32. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy.
Xylinas E; Rink M; Robinson BD; Lotan Y; Babjuk M; Brisuda A; Green DA; Kluth LA; Pycha A; Fradet Y; Faison T; Lee RK; Karakiewicz PI; Zerbib M; Scherr DS; Shariat SF
Eur J Cancer; 2013 May; 49(8):1889-97. PubMed ID: 23466126
[TBL] [Abstract][Full Text] [Related]
33. Does patient age affect survival after radical cystectomy?
Horovitz D; Turker P; Bostrom PJ; Mirtti T; Nurmi M; Kuk C; Kulkarni G; Fleshner NE; Finelli A; Jewett MA; Zlotta AR
BJU Int; 2012 Dec; 110(11 Pt B):E486-93. PubMed ID: 22551360
[TBL] [Abstract][Full Text] [Related]
34. The association of ABO blood type with disease recurrence and mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
Gershman B; Moreira DM; Tollefson MK; Frank I; Cheville JC; Thapa P; Tarrell RF; Thompson RH; Boorjian SA
Urol Oncol; 2016 Jan; 34(1):4.e1-9. PubMed ID: 26329815
[TBL] [Abstract][Full Text] [Related]
35. The importance of surgeon characteristics on impacting oncologic outcomes for patients undergoing radical cystectomy.
Bhindi B; Yu J; Kuk C; Sridhar SS; Hamilton RJ; Finelli A; Jewett MA; Evans A; Fleshner NE; Zlotta AR; Kulkarni GS
J Urol; 2014 Sep; 192(3):714-9. PubMed ID: 24594406
[TBL] [Abstract][Full Text] [Related]
36. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
Rogers CG; Palapattu GS; Shariat SF; Karakiewicz PI; Bastian PJ; Lotan Y; Gupta A; Vazina A; Gilad A; Sagalowsky AI; Lerner SP; Schoenberg MP
J Urol; 2006 Jun; 175(6):2048-53; discussion 2053. PubMed ID: 16697800
[TBL] [Abstract][Full Text] [Related]
38. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study.
Hermans TJ; Fransen van de Putte EE; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; de Wit R; Beerepoot LV; Verhoeven RH; van Rhijn BW
Eur J Cancer; 2016 Dec; 69():1-8. PubMed ID: 27814469
[TBL] [Abstract][Full Text] [Related]
39. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy.
Rink M; Lee DJ; Kent M; Xylinas E; Fritsche HM; Babjuk M; Brisuda A; Hansen J; Green DA; Aziz A; Cha EK; Novara G; Chun FK; Lotan Y; Bastian PJ; Tilki D; Gontero P; Pycha A; Baniel J; Mano R; Ficarra V; Trinh QD; Tagawa ST; Karakiewicz PI; Scherr DS; Sjoberg DD; Shariat SF;
BJU Int; 2013 Mar; 111(3 Pt B):E30-6. PubMed ID: 22938654
[TBL] [Abstract][Full Text] [Related]
40. Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score-weighted European multicentre study.
Vetterlein MW; Gild P; Kluth LA; Seisen T; Gierth M; Fritsche HM; Burger M; Protzel C; Hakenberg OW; von Landenberg N; Roghmann F; Noldus J; Nuhn P; Pycha A; Rink M; Chun FK; May M; Fisch M; Aziz A;
BJU Int; 2018 Jan; 121(1):101-110. PubMed ID: 28905486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
